Shares of Finch Therapeutics Group, Inc. (NASDAQ:FNCH – Get Free Report) dropped 1.7% on Wednesday . The company traded as low as $11.30 and last traded at $11.30. Approximately 606 shares were traded during trading, a decline of 30% from the average daily volume of 865 shares. The stock had previously closed at $11.50.
Finch Therapeutics Group Stock Down 1.7 %
The company has a market cap of $18.19 million, a PE ratio of -1.28 and a beta of 1.31. The stock has a 50-day moving average of $11.29 and a 200-day moving average of $10.25.
Finch Therapeutics Group Company Profile
Finch Therapeutics Group, Inc, a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company develops FIN-211, a microbiome candidate designed to address the gastrointestinal and behavioral symptoms of autism spectrum disorder; and FIN-524 for the prevention, diagnosis, theragnosis or treatment of diseases in humans, including ulcerative colitis; FIN-525 for the treatment of Crohn's disease; and other microbiome product candidates.
See Also
- Five stocks we like better than Finch Therapeutics Group
- Canadian Penny Stocks: Can They Make You Rich?
- How to Short Sell Stocks Like a Pro: Strategies and Tips
- What is a buyback in stocks? A comprehensive guide for investors
- 3 Steel Stocks Soaring After Tariff Announcements
- NYSE Stocks Give Investors a Variety of Quality OptionsÂ
- Top Analysts’ Picks for 2025: 3 of Morgan Stanley’s Favorites
Receive News & Ratings for Finch Therapeutics Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Finch Therapeutics Group and related companies with MarketBeat.com's FREE daily email newsletter.
